{"nctId":"NCT00707993","briefTitle":"Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics","startDateStruct":{"date":"2008-06"},"conditions":["Diabetes Mellitus"],"count":441,"armGroups":[{"label":"Alogliptin 25 mg QD","type":"EXPERIMENTAL","interventionNames":["Drug: Alogliptin"]},{"label":"Glipizide 5 mg QD","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Glipizide"]}],"interventions":[{"name":"Alogliptin","otherNames":["SYR110322","SYR-322"]},{"name":"Glipizide","otherNames":["Glucotrol"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Has a diagnosis of type 2 diabetes mellitus with either:\n\n  * Failed diet and exercise therapy alone as demonstrated by inadequate glycemic control while receiving no antidiabetic treatment within the two months prior to Screening, or\n  * Failed treatment with oral monotherapy alone (may include treatment with two or more antidiabetic agents if for less than 7 days) as demonstrated by inadequate glycemic control within the two months prior to Screening.\n* Body mass index greater than or equal to 23 kg/m2 and less than or equal to 45 kg/m2.\n* If regularly using other, non-excluded medications, must be on a stable dose for at least the 4 weeks prior to Screening.\n* Females of childbearing potential who are sexually active must agree to use a medically accepted means of contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.\n* Able and willing to monitor their own blood glucose concentrations with a home glucose monitor.\n* No major illness or debility that in the investigator's opinion prohibits the participant from completing the study.\n\nExclusion Criteria:\n\n* Systolic blood pressure greater than or equal to 160 mm Hg and/or diastolic pressure greater than or equal to 100 mm Hg.\n* Hemoglobin less than or equal to 12 g/dL for males or less than or equal to 10 g/dL for females.\n* Alanine aminotransferase greater than or equal to 3 times the upper limit of normal.\n* Calculated creatinine clearance less than or equal to 50 mL/min.\n* Thyroid-stimulating hormone level outside of the normal range.\n* History of cancer, other than squamous cell or basal cell carcinoma of the skin, that has not been in full remission for at least 5 years prior to Screening.\n* History of laser treatment for proliferative diabetic retinopathy within the 6 months prior to Screening.\n* History of treated diabetic gastroparesis, gastric banding, or gastric bypass surgery.\n* New York Heart Association Class III or IV heart failure regardless of therapy.\n* History of coronary angioplasty, coronary stent placement, coronary bypass surgery, or myocardial infarction within the 6 months prior to Screening.\n* History of any hemoglobinopathy that may affect determination of glycosylated hemoglobin.\n* History of infection with Human Immunodeficiency Virus.\n* History of a psychiatric disorder that will affect the participant's ability to participate in the study.\n* History of angioedema in association with use of angiotensin-converting enzyme inhibitors or angiotensin-II receptor inhibitors.\n* History of alcohol or substance abuse within the 2 years prior to Screening.\n* History of treatment with any weight-loss drugs or oral or systemically injected glucocorticoids within the 3 months prior to Screening.\n* Receipt of any investigational drug within the 30 days prior to Screening.\n* Prior treatment in an investigational study of alogliptin.\n* Clinically significant medical abnormality or disease or clinically significant abnormal findings at Screening (other than type 2 diabetes) that, in the opinion of the investigator, should exclude the participant from the study.\n* Has donated more than 400 mL of blood within the 90 days preceding their participation in the study.\n* Has hypersensitivity or has had an anaphylactic reaction(s) to any DPP-4 inhibitor drug.","healthyVolunteers":false,"sex":"ALL","minimumAge":"65 Years","maximumAge":"90 Years","stdAges":["OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Glycosylated Hemoglobin at Week 52.","description":"The change in the percentage of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 52 or final visit and glycosylated hemoglobin collected at baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":"0.063"},{"groupId":"OG001","value":"-0.09","spread":"0.067"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Glycosylated Hemoglobin","description":"The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at each week indicated including final visit relative to baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":"0.047"},{"groupId":"OG001","value":"-0.11","spread":"0.051"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.27","spread":"0.051"},{"groupId":"OG001","value":"-0.23","spread":"0.054"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.34","spread":"0.053"},{"groupId":"OG001","value":"-0.25","spread":"0.055"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.31","spread":"0.050"},{"groupId":"OG001","value":"-0.32","spread":"0.052"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.31","spread":"0.051"},{"groupId":"OG001","value":"-0.27","spread":"0.054"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.28","spread":"0.052"},{"groupId":"OG001","value":"-0.25","spread":"0.055"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.21","spread":"0.056"},{"groupId":"OG001","value":"-0.21","spread":"0.059"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.17","spread":"0.062"},{"groupId":"OG001","value":"-0.17","spread":"0.065"}]}]}]},{"type":"SECONDARY","title":"Incidence of Hypoglycemia","description":"Percentage of participants with at least one hypoglycemic episode during 52 week study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":null},{"groupId":"OG001","value":"26.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Marked Hyperglycemia (Fasting Plasma Glucose ≥200 mg Per dL).","description":"The number of participants with a fasting plasma glucose value ≥ to 200 mg per dL during the 52 week study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Hyperglycemic Rescue","description":"The number of participants requiring rescue for failing to achieve pre-specified glycemic targets during the 52 week study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose","description":"The change in the value of fasting plasma glucose collected at each week indicated including final visit relative to baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.8","spread":"1.93"},{"groupId":"OG001","value":"-5.0","spread":"1.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.7","spread":"1.93"},{"groupId":"OG001","value":"-7.6","spread":"1.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.9","spread":"1.76"},{"groupId":"OG001","value":"-8.7","spread":"1.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.2","spread":"1.84"},{"groupId":"OG001","value":"-9.9","spread":"1.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.9","spread":"1.85"},{"groupId":"OG001","value":"-11.4","spread":"1.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.8","spread":"1.78"},{"groupId":"OG001","value":"-8.7","spread":"1.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.9","spread":"1.97"},{"groupId":"OG001","value":"-6.2","spread":"1.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.4","spread":"1.98"},{"groupId":"OG001","value":"-5.7","spread":"1.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.6","spread":"2.13"},{"groupId":"OG001","value":"-7.4","spread":"2.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"2.24"},{"groupId":"OG001","value":"-4.2","spread":"2.26"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 2-hour Postprandial Glucose","description":"The change in postprandial (after eating a meal) glucose levels at week 52 relative to baseline. Standard 2-hour postprandial glucose (PPG) tests performed following an overnight fast and evaluated right before and after a 120-minute (2-hour) timeframe relative to ingestion of a standard oral glucose drink.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.80","spread":"5.530"},{"groupId":"OG001","value":"6.30","spread":"5.989"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.82","spread":"4.434"},{"groupId":"OG001","value":"7.17","spread":"4.804"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Proinsulin","description":"The change between the value of fasting proinsulin collected at each week indicated including final visit relative to baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.0","spread":"0.99"},{"groupId":"OG001","value":"1.0","spread":"1.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.6","spread":"1.49"},{"groupId":"OG001","value":"3.0","spread":"1.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.6","spread":"1.48"},{"groupId":"OG001","value":"3.1","spread":"1.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.9","spread":"1.42"},{"groupId":"OG001","value":"3.0","spread":"1.48"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Insulin","description":"The change between the value of insulin collected at each week indicated including final visit relative to baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.36","spread":"0.673"},{"groupId":"OG001","value":"0.84","spread":"0.707"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.41","spread":"1.548"},{"groupId":"OG001","value":"3.03","spread":"1.611"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.58","spread":"1.254"},{"groupId":"OG001","value":"1.53","spread":"1.305"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.72","spread":"1.731"},{"groupId":"OG001","value":"3.15","spread":"1.801"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Proinsulin/Insulin Ratio","description":"The change between the ratio value of proinsulin and insulin collected at each week indicated including final visit relative to baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.288","spread":"0.1035"},{"groupId":"OG001","value":"0.053","spread":"0.1092"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.253","spread":"0.4333"},{"groupId":"OG001","value":"0.562","spread":"0.4520"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.289","spread":"0.1500"},{"groupId":"OG001","value":"0.183","spread":"0.1565"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.155","spread":"0.0899"},{"groupId":"OG001","value":"-0.057","spread":"0.0938"}]}]}]},{"type":"SECONDARY","title":"Homeostasis Model Assessment of Beta Cell Function","description":"The change between homeostasis model assessment of beta cell function collected at each week indicated including final visit relative to baseline. Homeostasis model assessment of beta cell function measures beta cell function, calculated by a constant (20) times insulin, divided by fasting plasma glucose minus a constant (3.5).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.104","spread":"8.3062"},{"groupId":"OG001","value":"30.081","spread":"8.7264"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.136","spread":"9.7088"},{"groupId":"OG001","value":"31.669","spread":"10.0562"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.571","spread":"7.1395"},{"groupId":"OG001","value":"16.004","spread":"7.3950"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.755","spread":"13.8868"},{"groupId":"OG001","value":"35.281","spread":"14.3836"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight","description":"The change in body weight measured at each week indicated including final visit from baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.42","spread":"0.118"},{"groupId":"OG001","value":"0.55","spread":"0.122"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.52","spread":"0.142"},{"groupId":"OG001","value":"0.42","spread":"0.146"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.68","spread":"0.188"},{"groupId":"OG001","value":"0.66","spread":"0.193"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.72","spread":"0.211"},{"groupId":"OG001","value":"0.57","spread":"0.216"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.62","spread":"0.227"},{"groupId":"OG001","value":"0.60","spread":"0.233"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Serum Lipids (Total Cholesterol)","description":"The change in total cholesterol measured at each week indicated including final visit from baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.6","spread":"2.01"},{"groupId":"OG001","value":"-1.6","spread":"2.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.2","spread":"2.06"},{"groupId":"OG001","value":"-0.7","spread":"2.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"2.03"},{"groupId":"OG001","value":"0.1","spread":"2.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"2.07"},{"groupId":"OG001","value":"0.1","spread":"2.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"2.28"},{"groupId":"OG001","value":"-0.5","spread":"2.35"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Serum Lipids (High-Density Lipoprotein Cholesterol)","description":"The change in high-density lipoprotein cholesterol measured at each week indicated including final visit from baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.59"},{"groupId":"OG001","value":"1.2","spread":"0.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.47"},{"groupId":"OG001","value":"0.5","spread":"0.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"0.50"},{"groupId":"OG001","value":"0.2","spread":"0.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"0.59"},{"groupId":"OG001","value":"0.1","spread":"0.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.50"},{"groupId":"OG001","value":"0.3","spread":"0.51"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Serum Lipids (Low-Density Lipoprotein Cholesterol)","description":"The change in low-density lipoprotein cholesterol measured at each week indicated including final visit from baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.2","spread":"1.70"},{"groupId":"OG001","value":"-2.8","spread":"1.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":"1.75"},{"groupId":"OG001","value":"-2.4","spread":"1.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"1.67"},{"groupId":"OG001","value":"-1.1","spread":"1.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"1.79"},{"groupId":"OG001","value":"-0.8","spread":"1.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"1.83"},{"groupId":"OG001","value":"-1.4","spread":"1.88"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Serum Lipids (Triglycerides)","description":"The change in triglycerides measured at each week indicated including final visit from baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.8","spread":"5.04"},{"groupId":"OG001","value":"2.7","spread":"5.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.5","spread":"5.72"},{"groupId":"OG001","value":"7.5","spread":"5.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.3","spread":"4.74"},{"groupId":"OG001","value":"3.9","spread":"4.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.6","spread":"5.01"},{"groupId":"OG001","value":"5.5","spread":"5.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.2","spread":"5.27"},{"groupId":"OG001","value":"1.9","spread":"5.42"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in High Sensitivity C-reactive Protein","description":"The change between the high sensitivity C-reactive protein value collected at each week indicated including final visit from baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.45","spread":"0.699"},{"groupId":"OG001","value":"0.10","spread":"0.730"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.682"},{"groupId":"OG001","value":"0.47","spread":"0.706"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":"0.736"},{"groupId":"OG001","value":"0.53","spread":"0.762"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.656"},{"groupId":"OG001","value":"0.21","spread":"0.679"}]}]}]},{"type":"SECONDARY","title":"Incidence of Subjects Achieving Glycosylated Hemoglobin <=7%","description":"The percentage of participants with a value for the percentage of glycosylated hemoglobin (HbA1c; the percentage of hemoglobin that is bound to glucose) less than or equal to 6.5 and 7.0% during the 52 week study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.3","spread":null},{"groupId":"OG001","value":"18.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.8","spread":null},{"groupId":"OG001","value":"45.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Glycosylated Hemoglobin Decrease From Baseline.","description":"The percentage of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 0.5, 1.0, 1.5 and 2.0% during the 52 week study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.1","spread":null},{"groupId":"OG001","value":"29.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.6","spread":null},{"groupId":"OG001","value":"10.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":null},{"groupId":"OG001","value":"2.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":null},{"groupId":"OG001","value":"1.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":16,"n":222},"commonTop":["Urinary tract infection","Dizziness","Headache","Diarrhoea","Nasopharyngitis"]}}}